rhBMP-2 not alendronate combined with HA-TCP biomaterial and distraction osteogenesis enhance bone formation

Orthopaedic Surgery
First Online:
Received:

Abstract

Introduction

The long treatment duration of distraction osteogenesis (DO) usually causes some complications such as re-fracture, non-union. We have previously demonstrated that the combined use of biomaterial with distraction osteogenesis technique can enhance bone formation and consolidation. This study further tested whether the use of biological agents such as rhBMP-2 or alendronate together with biomaterials in DO will further promote bone formation.

Methods

A 1.0-cm tibial shaft was removed in the left tibia of 30 rabbits. The 1.0-cm defect gap was reduced to 0.5 cm and the remaining 0.5-cm defect gap was filled with 0.5-cm restorable hydroxyapatite/tri-calcium phosphates (HA/TCP) cylindrical block. The animals were divided into three groups with the following added on the HA/TCP block: Group A 50 μl of saline, Group B 75 μg rhBMP-2 in 50 μl of saline, Group C 250 μg alendronate in 50 μl saline. The tibia was then fixed with unilateral lengthener and lengthening started 7 days after at a rate of 1.0 mm/day for 5 days. All animals were terminated at day 37 following surgery. The excised bone specimens were subject to micro-CT, mechanical testing and histological examinations.

Results

Bone mineral density and content were significantly higher in Groups A and B compared to Group C and the mechanical properties of the regenerates in Group B were highest. Micro-CT and histological examinations also confirmed that the regenerates in Group B had the most advanced bone formation, consolidation and remodeling comparing to other groups.

Conclusion

The combined use of rhBMP-2 with HA-TCP biomaterial in DO has significantly enhanced bone formation and consolidation than using the HA-TCP biomaterials alone, whereas the use of alendronate has inhibitory effects on bone formation.

Keywords

Distraction osteogenesis HA-TCP rhBMP-2 Alendronate Bone defect 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank Mr. Jason Hendry, Millenium Biologix Corporation, Kingston, Canada for providing the cylindrical Skelite™ scaffolds for this study.

References

  1. 1.
    Moseley CF (1989) Leg lengthening. A. review of 30 years. Clin Orthop 247:38–43PubMedGoogle Scholar
  2. 2.
    Dahl MT, Gulli B, Berg T (1994) Complications of limb lengthening. A learning curve. Clin Orthop 301:10–18PubMedGoogle Scholar
  3. 3.
    Garcia CE, Olsen B, Ruiz Yague M et al (1992) Ilizarov technique: results and difficulties. Clin Orthop 283:116–123Google Scholar
  4. 4.
    Wang Y, Ni M, Tang PF et al (2009) Novel application of HA-TCP biomaterials in distraction osteogenesis shortened the lengthening time and promoted bone consolidation. J Orthop Res 27:477–482. doi: 10.1002/jor.20782 PubMedCrossRefGoogle Scholar
  5. 5.
    Urist MR (1965) Bone: formation by autoinduction. Science 150:893–899PubMedCrossRefGoogle Scholar
  6. 6.
    Sakou T (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22:591–603. doi: 10.1016/S8756-3282(98)00053-2 PubMedCrossRefGoogle Scholar
  7. 7.
    Welch RD, Jones AL, Bucholz RW et al (1998) Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 13:1483–1490. doi: 10.1359/jbmr.1998.13.9.1483 PubMedCrossRefGoogle Scholar
  8. 8.
    Yudell RM, Block MS (2000) Bone gap healing in the dog using recombinant human bone morphogenetic protein-2. J Oral Maxillofac Surg 58:761–766. doi: 10.1053/joms.2000.7261 PubMedCrossRefGoogle Scholar
  9. 9.
    Li G, Bouxsein ML, Luppen C et al (2002) Bone consolidation is enhanced by rhBMP-2 in a rabbit model of distraction osteogenesis. J Orthop Res 20:779–788. doi: 10.1016/S0736-0266(01)00166-8 PubMedCrossRefGoogle Scholar
  10. 10.
    Peter CP, Cook WO, Nunamaker DM et al (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74–79. doi: 10.1002/jor.1100140113 PubMedCrossRefGoogle Scholar
  11. 11.
    Li G, Simpson AHRW, Kenwright J et al (1999) Effect of lengthening rate on angiogenesis during distraction osteogenesis. J Orthop Res 17:362–367. doi: 10.1002/jor.1100170310 PubMedCrossRefGoogle Scholar
  12. 12.
    Li G, Simpson AHRW, Kenwright J et al (1997) Assessment of cell proliferation in regenerating bone during distraction osteogenesis at different distraction rates. J Orthop Res 15:765–772. doi: 10.1002/jor.1100150520 PubMedCrossRefGoogle Scholar
  13. 13.
    Wang Y, Wan C, Szoke G et al (2008) Local injection of thrombin-related peptide (TP508) in PPF/PLGA microparticles enhanced bone formation during distraction osteogenesis. J Orthop Res 26:539–546. doi: 10.1002/jor.20495 PubMedCrossRefGoogle Scholar
  14. 14.
    Watanabe K, Tsuchiya H, Sakurakichi K et al (2007) Bone transport using hydroxyapatite loaded with bone morphogenetic protein in rabbits. J Bone Joint Surg Br 89:1122–1129. doi: 10.1302/0301-620X.89B8.19003 PubMedCrossRefGoogle Scholar
  15. 15.
    Yamaguchi A, Katagiri T, Ikeda T et al (1991) Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113:681–687PubMedCrossRefGoogle Scholar
  16. 16.
    Li G, Cui Y, Mcllmurray L et al (2005) rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. J Orthop Res 23:680–685PubMedCrossRefGoogle Scholar
  17. 17.
    Li G (2004) New developments and insights learned from distraction osteogenesis. Curr Opin Orthop 15:325–330CrossRefGoogle Scholar
  18. 18.
    Bergstrom JD, Bostedor RG, Masarachia PJ (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231–241PubMedCrossRefGoogle Scholar
  19. 19.
    Little DG, Smith NC, Williams PR et al (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18:1300–1307. doi: 10.1359/jbmr.2003.18.7.1300 PubMedCrossRefGoogle Scholar
  20. 20.
    Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(d, l-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79(5):717–725PubMedCrossRefGoogle Scholar
  21. 21.
    Greiner S, Kadow-Romacker A, Wildemann B, Schwabe P, Schmidmaier G (2007) Bisphosphonates incorporated in a poly(d, l-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res 83(4):1184–1191CrossRefGoogle Scholar
  22. 22.
    Sloan AV, Martin JR, Li S et al (2010) Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 47(2):235–240. doi: 10.1016/j.bone.2010.05.015 PubMedCrossRefGoogle Scholar
  23. 23.
    Matos MA, Tannuri U, Guarniero R et al (2010) The effect of zoledronate during bone healing. J Orthop Traumatol 11(1):7–12. doi: 10.1007/s10195-010-0083-1 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryGeneral Hospital of Chinese People’s Liberation ArmyBeijingPeople’s Republic of China
  2. 2.Department of Orthopaedics and Traumatology, Faculty of MedicineThe Chinese University Hong Kong, Clinical Sciences Building, Prince of Wales HospitalHong KongPeople’s Republic of China
  3. 3.Stem Cells and Regenerative Program, School of Biomedical Sciences, The Li Ka Shing Institute of Health SciencesThe Chinese University of Hong Kong, Prince of Wales HospitalHong KongPeople’s Republic of China
  4. 4.CUHK-WHO Collaborating Centre for Sports Medicine and Health PromotionThe Chinese University Hong Kong, Clinical Sciences Building, Prince of Wales HospitalHong KongPeople’s Republic of China

Personalised recommendations